UBS/CALL/ELI LILLY & CO/1000.001/0.01/20.12.24 | Market Closed - Swiss Exchange 11:20:00 2024-07-16 am EDT | ||
| 0.62 CHF | -1.59% |
|
| Current month | +31.91% | ||
| 1 month | +55.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-07-16 | 0.62 | -1.59% |
| 24-07-15 | 0.63 | +8.62% |
| 24-07-12 | 0.58 | +1.75% |
| 24-07-11 | 0.57 | +3.64% |
| 24-07-10 | 0.55 | +12.24% |
Delayed Quote Swiss Exchange
Last update July 16, 2024 at 11:20 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | UBS |
| LLYHQU | |
| ISIN | CH1327379942 |
| Date issued | 2024-02-19 |
| Strike | 1,000 $ |
| Maturity | 2024-12-20 (157 Days) |
| Parity | 100 : 1 |
| Emission price | 0.25 CHF |
| Emission volume | N/A |
| Settlement | cash |
| Currency | CHF |
Technical Indicators
| Highest since issue | 0.63 CHF |
|---|---|
| Lowest since issue | 0.16 CHF |
| Spread | 0.01 CHF |
| Spread % | 1.61% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
941.6
USD
Average target price
893.8
USD
Spread / Average Target
-5.08%
- Stock Market
- Warrants
- LLYHQU Warrant
